

DDA Registry
PMB Medical

DDA 76-2102

27 April 1976

MEMORANDUM FOR: Acting General Counsel
FROM : John N. McMahon, Associate Deputy
Director for Administration
SUBJECT : Executive Order Restriction on Drug
Experimentation
REFERENCE : Memo dtd 13 Apr 76 to Acting GC fr
DDA, same subj (DDA 76-1826)

In addition to the wonderful observations made
in reference memo, this Directorate wishes to assure
you that we do not have any experimentation under way
nor do we contemplate any which would require
compliance with Executive Order 11905.

John N. McMahon

Distribution:

Orig & 1 - Acting GC

- ~~1~~ - DDA Subject w/ref and background
- 1 - DDA Chrono
- 1 - JNM Chrono

ADDA:JNMcMahon:kmg (27 Apr 76)

DDA Registry
File *Medical*

DDA 76-1826

13 April 1976

MEMORANDUM FOR: Acting General Counsel

FROM : John F. Blake
Deputy Director for Administration

SUBJECT : Executive Order Restriction on Drug
Experimentation

REFERENCE : Memo dtd 7 Apr 76 to DDS&T, Acting DDO,
DDA and IG fr Acting GC, same subj
(OGC 76-1741)

1. We have no problems with the liberal interpretations of the guidelines as set forth in E.O. 11905 on the subject matter. However, we do subscribe to the desire that the Agency live within the spirit of the intent and not just the cold, hard words.

2. The Director of Medical Services raises an interesting point, however, that certainly merits addressing. He notes that the Agency's difficulties with respect to drug experimentation in the past stem from either failure to monitor or follow precisely existing guidelines and that the key to the Agency's future activities should rest in a mechanism which permits the Director to be assured that the use of drugs and other noxious substances or techniques follow acceptable ethical as well as legal standards.

3. Accordingly, we recommend that an inter-Directorate committee be established, certainly including Medical Services, whose responsibility would be to monitor and follow all activities of the Agency regarding the use or R&D of drugs and other noxious substances to ensure that those activities are well within the limitations of existing guidelines. We exclude, of course, the prescription or application of drugs for medicinal purposes.

John F. Blake

for John F. Blake

Distribution:

Orig & 1 - Acting GC
1 - DDS&T
1 - D/MS

1 - DDA Subject w/ref(DDA 76-1771) &
1 - DDA Chrono OMS memo
1 - JNM Chrono

STATINTL

Approved For Release 2002/05/07 : CIA-RDP79-00498A000200120040-2

Approved For Release 2002/05/07 : CIA-RDP79-00498A000200120040-2